Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

41.50
-0.8100-1.91%
Volume:387.59K
Turnover:16.07M
Market Cap:3.34B
PE:29.76
High:42.07
Open:42.00
Low:41.04
Close:42.31
52wk High:60.91
52wk Low:28.25
Shares:80.39M
Float Shares:78.97M
Volume Ratio:0.61
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.40
PE(LYR):50.61

Loading ...

Veracyte (VCYT) Receives a Buy from Piper Sandler

TIPRANKS
·
Yesterday

Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 11

Veracyte price target lowered to $54 from $66 at Piper Sandler

TIPRANKS
·
Aug 04

Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

Simply Wall St.
·
Aug 04

Veracyte is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Aug 04

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

TIPRANKS
·
Aug 03

Veracyte falls -24.0%

TIPRANKS
·
Jul 31

Needham Raises Price Target on Veracyte to $69 From $57, Keeps Buy Rating

MT Newswires Live
·
Jul 31

Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating

TIPRANKS
·
Jul 31

Veracyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised

MT Newswires Live
·
Jul 31

GUIDANCE: (VCYT) Veracyte Now Expects Full Year 2026 Revenue Range $590 Million - $596 Million, vs. FactSet Est of $586.4 Million

MT Newswires Live
·
Jul 31

Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M

TIPRANKS
·
Jul 31

Veracyte Q2 FY26 Swings to GAAP Net Income of $25.5 Million; Revenue Rises 15% to $150.3 Million

Reuters
·
Jul 31

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million

Reuters
·
Jul 31

Veracyte Q2 Adj. EPS $0.54 Beats $0.24 Estimate, Sales $150.321M Beat $144.554M Estimate

Benzinga Earnings
·
Jul 31

Veracyte Outlook 2026 - Continues to Expect Adjusted Ebitda Margin to be Greater than 26%

THOMSON REUTERS
·
Jul 31

Veracyte Q2 EPS USD 0.31

THOMSON REUTERS
·
Jul 31

Veracyte Outlook FY Revenue Growth 14-15%

THOMSON REUTERS
·
Jul 31